BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29459862)

  • 1. Immunotherapy for Dogs: Running Behind Humans.
    Klingemann H
    Front Immunol; 2018; 9():133. PubMed ID: 29459862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Dogs: Still Running Behind Humans.
    Klingemann H
    Front Immunol; 2021; 12():665784. PubMed ID: 34421888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Immunotherapies.
    Bergman PJ
    Vet Clin North Am Small Anim Pract; 2019 Sep; 49(5):881-902. PubMed ID: 31186125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Role for Dogs in Advancing Cancer Immunotherapy Research.
    Dow S
    Front Immunol; 2019; 10():2935. PubMed ID: 32010120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing T cell cancer immunotherapy in the dog with lymphoma.
    O'Connor CM; Wilson-Robles H
    ILAR J; 2014; 55(1):169-81. PubMed ID: 24936037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment.
    Brill SA; Thamm DH
    Vet Comp Oncol; 2021 Sep; 19(3):420-427. PubMed ID: 34169631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for canine cancer--is it time to go back to the future?
    Killick DR; Stell AJ; Catchpole B
    J Small Anim Pract; 2015 Apr; 56(4):229-41. PubMed ID: 25704119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy.
    Bergman PJ
    Vet Clin North Am Small Anim Pract; 2010 May; 40(3):507-18. PubMed ID: 20471533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive cell transfer: new perspective treatment in veterinary oncology.
    Bujak JK; Pingwara R; Nelson MH; Majchrzak K
    Acta Vet Scand; 2018 Oct; 60(1):60. PubMed ID: 30305130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational oncotargets for immunotherapy: From pet dogs to humans.
    Mestrinho LA; Santos RR
    Adv Drug Deliv Rev; 2021 May; 172():296-313. PubMed ID: 33705879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs.
    Yannelli JR; Wouda R; Masterson TJ; Avdiushko MG; Cohen DA
    Vet Immunol Immunopathol; 2016 Dec; 182():95-100. PubMed ID: 27863558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cells for Snoopy: pet medicines spark a biotech boom.
    Ledford H
    Nature; 2016 Jun; 534(7607):303-4. PubMed ID: 27306165
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence-based integrative medicine in clinical veterinary oncology.
    Raditic DM; Bartges JW
    Vet Clin North Am Small Anim Pract; 2014 Sep; 44(5):831-53. PubMed ID: 25174902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in veterinary oncology.
    Bergman PJ
    Vet Clin North Am Small Anim Pract; 2014 Sep; 44(5):925-39. PubMed ID: 25174908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision Medicine in Veterinary Science.
    Chon E; Hendricks W; White M; Rodrigues L; Haworth D; Post G
    Vet Clin North Am Small Anim Pract; 2024 May; 54(3):501-521. PubMed ID: 38212188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.
    Nguyen SM; Thamm DH; Vail DM; London CA
    Vet Comp Oncol; 2015 Sep; 13(3):176-83. PubMed ID: 23534501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Owner assessment of therapeutic interventions for canine atopic dermatitis: a long-term retrospective analysis.
    Dell DL; Griffin CE; Thompson LA; Griffies JD
    Vet Dermatol; 2012 Jun; 23(3):228-e47. PubMed ID: 22575021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging Comparative Oncology in the Hopes of Improving Therapies for Breast Cancer.
    Khanna C
    Semin Oncol; 2017 Aug; 44(4):301. PubMed ID: 29526259
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.
    Barth SM; Schreitmüller CM; Proehl F; Oehl K; Lumpp LM; Kowalewski DJ; Di Marco M; Sturm T; Backert L; Schuster H; Stevanović S; Rammensee HG; Planz O
    PLoS One; 2016; 11(11):e0167017. PubMed ID: 27893789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of immunotherapy for canine atopic dermatitis: a review.
    DeBoer DJ
    Vet Dermatol; 2017 Feb; 28(1):25-e6. PubMed ID: 28133873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.